Structure-activity relationship studies of sulfonylpiperazine analogues as novel negative allosteric modulators of human neuronal nicotinic receptors

Journal of Medicinal Chemistry

Volumn 54, Issue 24, 2011, Pages 8681-8692

  Henderson, Brandon J ^a   Carper, Daniel J ^a   González Cestari, Tatiana F ^a   Yi, Bitna ^a   Mahasenan, Kiran ^a   Pavlovicz, Ryan E ^a   Dalefield, Martin L ^a   Coleman, Robert S ^a   Li, Chenglong ^a   McKay, Dennis B ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(4 FLUOROPHENYL)SULFONYL]PIPERAZINE; 2 [4 [(2 FLUOROPHENYL)SULFONYL]PIPERAZIN 1 YL] N (1H PYRAZOL 3 YL)ACETAMIDE; 2 [4 [(2 FLUOROPHENYL)SULFONYL]PIPERAZIN 1 YL] N (4 METHOXYPHENYL)ACETAMIDE; 2 [4 [(4 FLUOROPHENYL)SULFONYL]PIPERAZIN 1 YL] N (1H INDAZOL 5 YL)ACETAMIDE; 2 [4 [(4 FLUOROPHENYL)SULFONYL]PIPERAZIN 1 YL] N (1H PYRAZOL 3 YL)ACETAMIDE; 2 [4 [(4 FLUOROPHENYL)SULFONYL]PIPERAZIN 1 YL] N (4 METHOXYPHENYL)ACETAMIDE; 2 [4 [(4 FLUOROPHENYL)SULFONYL]PIPERAZIN 1 YL] N PHENYLACETAMIDE; 2 [4 [(4 FLUOROPHENYL)SULFONYL]PIPERAZIN 1 YL]ACETIC ACID; 2 BROMO N (2 FLUOROPHENYL)ACETAMIDE; 4 [2 [4 [(2 FLUOROPHENYL)SULFONYL]PIPERAZIN 1 YL]ACETAMIDO]BENZOIC ACID; ACETAMIDE DERIVATIVE; METHYL 4 [2 [4 [(2 FLUOROPHENYL)SULFONYL]PIPERAZIN 1 YL]ACETAMIDO]BENZOATE; N (1H PYRAZOL 3 YL) 2 [4 (PYRIDIN 3 YLSULFONYL)PIPERAZIN 1 YL]ACETAMIDE; N (2 FLUOROPHENYL) 2 [4 (PHENYLSULFONYL)PIPERAZIN 1 YL]ACETAMIDE; N (2 FLUOROPHENYL) 2 [4 (PYRIDIN 3 YLSULFONYL)PIPERAZIN 1 YL]ACETAMIDE; N (2 FLUOROPHENYL) 2 [4 [(2 FLUOROPHENYL)SULFONYL]PIPERAZIN 1 YL]ACETAMIDE; N (2 FLUOROPHENYL) 2 [4 [(4 FLUOROPHENYL)SULFONYL]PIPERAZIN 1 YL]ACETAMIDE; N (2 FLUOROPHENYL) 2 [4 [(4 METHOXYPHENYL)SULFONYL]PIPERAZIN 1 YL]ACETAMIDE; N (4 FLUOROPHENYL) 2 [4 [(2 FLUOROPHENYL)SULFONYL]PIPERAZIN 1 YL]ACETAMIDE; N (4 FLUOROPHENYL) 2 [4 [(4 FLUOROPHENYL)SULFONYL]PIPERAZIN 1 YL]ACETAMIDE; N (4 FLUOROPHENYL) 2 [4 [(4 METHOXYPHENYL)SULFONYL]PIPERAZIN 1 YL]ACETAMIDE; N (4 METHOXYPHENYL) 2 [4 (PYRIDIN 3 YLSULFONYL)PIPERAZIN 1 YL]ACETAMIDE; N [(1,1' BIPHENYL) 2 YL] 2 [4 [(2 FLUOROPHENYL)SULFONYL]PIPERAZIN 1 YL]ACETAMIDE; N [(1,1' BIPHENYL) 2 YL] 2 [4 [(4 FLUOROPHENYL)SULFONYL]PIPERAZIN 1 YL]ACETAMIDE; N PHENYL 2 [4 (PHENYLSULFONYL)PIPERAZIN 1 YL]ACETAMIDE; NICOTINIC RECEPTOR; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NERVE CELL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; CALCIUM; CELL LINE; HUMANS; NEURONS; PIPERAZINES; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 84055211763     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201294r     Document Type: Article

References (33)

1. Lloyd, G. K.; Williams, M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J. Pharmacol. Exp. Ther. 2000, 292, 461-467.
2. Schuller, H. M. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat. Rev. Cancer 2009, 9, 195-205.
3. Improgo, M. R. D.; Scofield, M. D.; Tapper, A. R.; Gardner, P. D. The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: dual role in nicotine addiction and lung cancer. Prog. Neurobiol. 2010, 92, 212-226.
4. Gotti, C.; Riganti, L.; Vailati, S.; Clementi, F. Brain neuronal nicotinic receptors as new targets for drug discovery. Curr. Pharm. Des. 2006, 12, 407-428.
5. Rice, M. E.; Cragg, S. J. Nicotine amplifies reward-related dopamine signals in striatum. Nat. Neurosci. 2004, 7, 583-584.
6. Cooper, E.; Couturier, S.; Ballivet, M. Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature 1991, 350, 235-238.
7. Anand, R.; Conroy, W. G.; Schoepfer, R.; Whiting, P.; Lindstrom, J. Neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quaternary structure. J. Biol. Chem. 1991, 266, 11192-11198.
8. Lukas, R. J.; Changeux, J.-P.; le Novère, N.; Albuquerque, E. X.; Balfour, D. J. K.; Berg, D. K.; Bertrand, D.; Chiappinelli, V. A.; Clarke, P. B. S.; Collins, A. C.; Dani, J. A.; Grady, S. R.; Kellar, K. J.; Lindstrom, J. M.; Marks, M. J.; Quik, M.; Taylor, P. W.; Wonnacott, S. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol. Rev. 1999, 51, 397-401.
9. Jensen, A. A.; Frolund, B.; Liljefors, T.; Krogsgaard-Larsen, P. Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J. Med. Chem. 2005, 48, 4705-4745.
10. Albuquerque, E. X.; Pereira, E. F. R.; Alkondon, M.; Rogers, S. W. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev. 2009, 89, 73-120.
11. * receptors: sufficient for reward, tolerance, and sensitization. Science 2004, 306, 1029-1032.
12. Picciotto, M. R.; Zoli, M.; Rimondini, R.; Lena, C.; Marubio, L. M.; Pich, E. M.; Fuxe, K.; Changeux, J.-P. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 1998, 391, 173-177.
13. Knight, C.; Howard, P.; Baker, C. L.; Marton, J. P. The cost-effectiveness of an extended course (12 + 12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO Model. Value Health 2009, 13, 209-214.
14. Mihalak, K. B.; Carroll, F. I.; Luetje, C. W. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol. Pharmacol. 2006, 70, 801-805.
15. Rollema, H.; Chambers, L. K.; Coe, J. W.; Glowa, J.; Hurst, R. S.; Lebel, L. A.; Lu, Y.; Mansbach, R. S.; Mather, R. J.; Rovetti, C. C.; Sands, S. B.; Schaeffer, E.; Schulz, D. W.; Tingley, F. D.; Williams, K. E. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007, 52, 985-994.
16. Fiore, M. C.; McCarthy, D. E.; Jackson, T. C.; Zehner, M. E.; Jorenby, D. E.; Mielke, M.; Smith, S. S.; Guiliani, T. A.; Baker, T. B. Integrating smoking cessation treatment into primary care: an effectiveness study. Prev. Med. 2004, 38, 412-420.
17. Taly, A.; Corringer, P.-J.; Guedin, D.; Lestage, P.; Changeux, J.-P. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat. Rev. Drug Discovery 2009, 8, 733-750.
18. *-, and α7-nicoine acetylcholine receptors. Neuropharmacology 2010, 58, 1054-1066.
19. López-Hernández, G. Y.; Thinschmidt, J. S.; Zheng, G.; Zhang, Z.; Crooks, P. A.; Dwoskin, L. P.; Papke, R. L. Selective inhibition of acetylcholine-evoked responses of α7 neuronal nicotinic acetylcholine receptors by novel tris- and tetrakis-azaaromatic quaternary ammonium antagonists. Mol. Pharmacol. 2009, 76, 652-666.
20. Yoshimura, R. F.; Hogenkamp, D. J.; Li, W. Y.; Tran, M. B.; Belluzzi, J. D.; Whittemore, E. R.; Leslie, F. M.; Gee, K. W. Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats. J. Pharmacol. Exp. Ther. 2007, 323, 907-915.
21. Weltzin, M. M.; Schulte, M. K. Pharmacological characterization of the allosteric modulator desformylflustrabromine and its interaction with α4β2 neuronal nicotinic acetylcholine receptor orthosteric ligands. J. Pharmacol. Exp. Ther. 2010, 334, 917-926.
22. Hansen, S. B.; Taylor, P. Galanthamine and non-competitive inhibitor binding to ACh-binding protein: evidence for a binding site on non-α-subunit interfaces of heteromeric neuronal nicotinic receptors. J. Mol. Biol. 2007, 369, 895-901.
23. Rose, J. E.; Behm, F. M.; Westman, E. C.; Levin, E. D.; Stein, R. M.; Ripka, G. V. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther. 1994, 56, 86-99.
24. Watkins, S. S.; Epping-Jordan, M. P.; Koob, G. F.; Markou, A. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol., Biochem. Behav. 1999, 62, 743-751.
25. Henderson, B. J.; Pavlovicz, R. E.; Allen, J. D.; Gonzalez-Cestari, T. F.; Orac, C. M.; Bonnell, A. B.; Zhu, M. X.; Boyd, R. T.; Li, C.; Bergmeier, S. C.; McKay, D. B. Negative allosteric modulators that target human α4β2 neuronal nicotinic receptors. J. Pharmacol. Exp. Ther. 2010, 334, 761-774.
26. Pavlovicz, R. E.; Henderson, B. J.; Bonnell, A. B.; Boyd, R. T.; McKay, D. B.; Li, C. Identification of a novel negative allosteric site on human α4β2 and α3β4 neuronal nicotinic acetylcholine receptors. PLoS One 2011, 6 (9), e24949.
27. Mahasenan, K. V.; Pavlovicz, R. E.; Henderson, B. J.; González-Cestari, T. F.; Yi, B.; McKay, D. B.; Li, C. Discovery of novel α4β2 neuronal nicotinic receptor modulators through structure-based virtual screening. ACS Med. Chem. Lett. 2011, 2, 855-860.
28. Wang, Z.; Wu, B.; Kuhen, K. L.; Bursulaya, B.; Nguyen, T. N.; Nguyen, D. G.; He, Y. Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nuleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 4174-4177.
29. Xie, H.; Ng, D.; Savinov, S. N.; Dey, B.; Kwong, P. D.; Wyatt, R.; Smith, A. B.; Hendrickson, W. A. Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus. J. Med. Chem. 2007, 50, 4898-4908.
30. de Castro Barbosa, M. L.; de Albequerque Melo, G. M.; da Silva, Y. K. C.; de Oliveira Lopes, R.; de Souza, E. T.; de Queiroz, A. C.; Smaniotto, S.; Alexandre-Moreira, M. S.; Barreiro, E. J.; Lima, L. M. Synthesis and pharmacological evaluation of N-phenyl-acetamide sulfonamides designed as novel non-hepatotoxic analgesic candidates. Eur. J. Med. Chem. 2009, 44, 3612-3620.
31. Carpino, L. A.; El-Fahm, A. The diisopropylcarbodiimide/1-hydroxy-7- azabenzotriazole system: segment coupling and stepwise peptide assembly. Tetrahedron 1999, 55, 6813-6830.
32. McKay, D. B.; Chang, C.; González-Cestari, T. F.; McKay, S. B.; El-Hajj, R. A.; Bryant, D. L.; Zhu, D. L.; Swaan, P. W.; Arason, K. M.; Pulipaka, A. B.; Orac, C. M.; Bergmeier, S. C. Analogs of methyllycaconitine as novel noncompetitive inhibitors of nicotinic receptors: pharmacological characterization, computational modeling, and pharmacophore development. Mol. Pharmacol. 2007, 71, 1288-1297.
33. González-Cestari, T. F.; Henderson, B. J.; Pavlovicz, R. E.; McKay, S. B.; El-Hajj, R. A.; Pulipaka, A. B.; Orac, C. M.; Reed, D. D.; Boyd, R. T.; Zhu, M. X.; Li, C.; Bergmeier, S. C.; McKay, D. B. Effect of novel negative allosteric modulators of neuronal nicotinic receptors on cells expressing native and recombinant nicotinic receptors: implications for drug discovery. J. Pharmacol. Exp. Ther. 2009, 328, 504-515.